- Reference code :
- wf4984
- Published date :
-
28 June 2005
- Expired date :
-
13 November 2032
AstraZeneca today announced that 'Arimidex' (anastrozole) has been granted a new indication from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, which has acted as the Reference Member State for the European Mutual Recognition Variation Procedure leading to further approvals in five other European countries - Austria, Germany, Italy, Portugal and Spain.
The new indication - 'Adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer' - will mean that more postmenopausal women whose breast cancer is fuelled by the hormone, oestrogen - about 75 per cent of all postmenopausal cases - are now eligible to receive Arimidex after surgery to prevent their disease returning. Arimidex offers a 26 per cent reduction in the risk of breast cancer coming back compared with tamoxifen, the gold standard for breast cancer management of 30 years standing.
"This is the moment we have been waiting for," said Mr Rob Carpenter, Consultant Surgical Oncologist at St Bartholomew's Hospital, London. "It has recently been confirmed that Arimidex offers crucial advantages over tamoxifen, in terms of enabling patients to stay disease free for longer. However, it is only now, with the new indication that more postmenopausal women with breast cancer may benefit from this drug at the earliest opportunity after breast surgery. This news marks the beginning of a whole new era in breast cancer management."
The MHRA granted the indication on the basis of data from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial, the largest breast cancer trial ever conducted. These data demonstrate that Arimidex reduces the risk of breast cancer recurring anywhere in the body by an additional 26 per cent (HR =0.74; p= <0.0002), over and above the 50 per cent reduction provided by tamoxifen. Moreover, it may prevent life-threatening 'distant' recurrence of the disease (i.e. secondary cancers outside the breast) by an additional 16 per cent compared with tamoxifen though this difference has not yet reached statistical significance (HR=0.84; p=0.056).
A new analysis from the ATAC trial, presented at the American Society of Clinical Oncologists in May 2005, demonstrated that the risk of breast cancer recurrence reaches a peak in the first two years after a patient receives surgery. This supports previous research clearly demonstrating the peak in the risk of recurrence in the first two to three years.
Women treated with Arimidex immediately after surgery saw a reduced risk of recurrence in the first 18-24 months at a time when recurrences are at their highest level. The study authors concluded that this benefit in the first two years of treatment would be lost if patients did not start with an aromatase inhibitor immediately post-surgery.
Arimidex has also been shown to have a favourable side effect profile versus tamoxifen, both in terms of serious life threatening side effects such as blood clots, stroke and cancer of the womb lining as well as symptoms that are important to women, such as hot flushes and vaginal discharge. However, women taking Arimidex experienced an increased risk of joint pain and fracture, although fracture rates reported in the ATAC trial are similar to those seen in age-matched postmenopausal women. It is not known whether the fracture rates seen are due to a protective effect of tamoxifen, a specific effect of Arimidex or both.
In 2004, Arimidex's worldwide sales increased by 48 per cent to $811 million, of which $358 million were in Europe.
Media Enquiries:
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033
Investor Enquiries:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Notes to Editors:
In the UK, Arimidex (anastrozole) is approved for use in the adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. It has been licensed for the treatment of advanced breast cancer since 1995, and now has over a million patient years experience worldwide.
The ATAC trial compares five years of treatment with tamoxifen to five years of treatment with anastrozole, in women newly diagnosed with early breast cancer. Eighty-four per cent of patients in the trial had tumours, which are known to respond to hormonal treatment.
"This is the moment we have been waiting for," said Mr Rob Carpenter, Consultant Surgical Oncologist at St Bartholomew's Hospital, London. "It has recently been confirmed that Arimidex offers crucial advantages over tamoxifen, in terms of enabling patients to stay disease free for longer. However, it is only now, with the new indication that more postmenopausal women with breast cancer may benefit from this drug at the earliest opportunity after breast surgery. This news marks the beginning of a whole new era in breast cancer management."
The MHRA granted the indication on the basis of data from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial, the largest breast cancer trial ever conducted. These data demonstrate that Arimidex reduces the risk of breast cancer recurring anywhere in the body by an additional 26 per cent (HR =0.74; p= <0.0002), over and above the 50 per cent reduction provided by tamoxifen. Moreover, it may prevent life-threatening 'distant' recurrence of the disease (i.e. secondary cancers outside the breast) by an additional 16 per cent compared with tamoxifen though this difference has not yet reached statistical significance (HR=0.84; p=0.056).
A new analysis from the ATAC trial, presented at the American Society of Clinical Oncologists in May 2005, demonstrated that the risk of breast cancer recurrence reaches a peak in the first two years after a patient receives surgery. This supports previous research clearly demonstrating the peak in the risk of recurrence in the first two to three years.
Women treated with Arimidex immediately after surgery saw a reduced risk of recurrence in the first 18-24 months at a time when recurrences are at their highest level. The study authors concluded that this benefit in the first two years of treatment would be lost if patients did not start with an aromatase inhibitor immediately post-surgery.
Arimidex has also been shown to have a favourable side effect profile versus tamoxifen, both in terms of serious life threatening side effects such as blood clots, stroke and cancer of the womb lining as well as symptoms that are important to women, such as hot flushes and vaginal discharge. However, women taking Arimidex experienced an increased risk of joint pain and fracture, although fracture rates reported in the ATAC trial are similar to those seen in age-matched postmenopausal women. It is not known whether the fracture rates seen are due to a protective effect of tamoxifen, a specific effect of Arimidex or both.
In 2004, Arimidex's worldwide sales increased by 48 per cent to $811 million, of which $358 million were in Europe.
Further enquiries to:
Media Enquiries:
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033
Investor Enquiries:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Notes to Editors:
In the UK, Arimidex (anastrozole) is approved for use in the adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. It has been licensed for the treatment of advanced breast cancer since 1995, and now has over a million patient years experience worldwide.
The ATAC trial compares five years of treatment with tamoxifen to five years of treatment with anastrozole, in women newly diagnosed with early breast cancer. Eighty-four per cent of patients in the trial had tumours, which are known to respond to hormonal treatment.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 06:58 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
